Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction

Heart

Volumn 97, Issue 11, 2011, Pages 892-898

  Klip, IJsbrand T ^a   Voors, Adriaan A ^a   Anker, Stefan D ^b,c   Hillege, Hans L ^a   Struck, Joachim ^d,e   Squire, Iain ^f,g   Van Veldhuisen, Dirk J ^a   Dickstein, Kenneth ^h,i  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

^d THERMO FISHER SCIENTIFIC   (Germany)

^e University of Leicester ^*  (United Kingdom)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

^g GLENFIELD HOSPITAL   (United Kingdom)

^h STAVANGER UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; PROADRENOMEDULLIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEATH; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FEMALE; HEART ARREST; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RESUSCITATION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STROKE;

ADRENOMEDULLIN; AGED; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 79955926423     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.210948     Document Type: Article

References (34)

1. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824-39.
2. Hogenhuis J, Voors AA, Jaarsma T, et al. Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur J Heart Fail 2005;7:81-6. (Pubitemid 40092496)
3. Hogenhuis J, Voors AA, Jaarsma T, et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail 2007;9:787-94. (Pubitemid 47212827)
4. Giamouzis G, Kalogeropoulos AP, Georgiopoulou VV, et al. Incremental value of renal function in risk prediction with the Seattle Heart Failure Model. Am Heart J 2009;157:299-305.
5. Bruins S, Fokkema MR, Römer JW, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-8. (Pubitemid 39425842)
6. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85. (Pubitemid 29384167)
7. Nakamura M, Yoshida H, Makita S, et al. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation 1997;95:1214-21.
8. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553-60. (Pubitemid 23227359)
9. Nicholls MG, Charles CJ, Lainchbury JG, et al. Adrenomedullin in heart failure. Hypertens Res 2003;26(Suppl):135-40.
10. Jougasaki M, Rodeheffer RJ, Redfield MM, et al. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 1996;97:2370-6. (Pubitemid 26165726)
11. Kato J, Kobayashi K, Etoh T, et al. Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab 1996;81:180-3. (Pubitemid 26035022)
12. Elmas E, Lang S, Dempfle CE, et al. Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction. Int J Cardiol 2008;128:107-11. (Pubitemid 351905763)
13. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-9.
14. Hinson JP, Kapas S, Smith DM, et al. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000;21:138-67. (Pubitemid 32275593)
15. Struck J, Tao C, Morgenthaler NG, et al. Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004;25:1369-72. (Pubitemid 39180069)
16. Khan SQ, O'Brien RJ, Struck J, et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2007;49:1525-32. (Pubitemid 46517963)
17. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-76.
18. Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007;13:42-9. (Pubitemid 46343794)
19. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752-60.
20. Morgenthaler NG, Struck J, Alonso C, et al. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51:1823-9. (Pubitemid 41368172)
21. Karl J, Borgya A, Gallusser A, et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999;230:177-81. (Pubitemid 29279370)
22. Loke I, Squire IB, Davies JE, et al. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Failure 2003;5:599-606. (Pubitemid 38043963)
23. DeLong ER, DeLong DM, Clarke-Pearson DL, et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
24. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new biomarker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72. (Pubitemid 351193639)
25. Voors AA, von Haehling S, Anker SD, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009;30:1187-94.
26. Sugo S, Minamino N, Kangawa K, et al. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun 1994;201:1160-6. (Pubitemid 24234212)
27. Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000;101:498-503. (Pubitemid 30080863)
28. Jougasaki M, Wei CM, McKinley LJ, et al. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995;92:286-9.
29. Katayama T, Nakashima H, Furudono S, et al. Evaluation of neurohumoral activation (adrenomedullin, BNP, catecholamines, etc.) in patients with acute myocardial infarction. Intern Med 2004;43:1015-22. (Pubitemid 39619115)
30. Adlbrecht C, Hülsmann M, Strunk G, et al. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure patients. Eur J Heart Fail 2009;11:361-6.
31. Meander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302:49-57.
32. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006;52:1528-38. (Pubitemid 44148316)
33. Van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-24. (Pubitemid 44345127)
34. Dhillon OS, Khan SQ, Narayan HK, et al. Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. J Am Coll Cardiol 2010;56:125-33.